• LeMaitre Vascular, Inc. recently reported fourth-quarter 2025 sales of US$64.45 million and net income of US$15.58 million, alongside full-year 2025 sales of US$249.6 million and net income of US$57.73 million, and announced a higher quarterly dividend of US$0.25 per share plus a share repurchase program of up to US$100 million through February 18, 2027.
• In addition, the company issued 2026 guidance that points to higher sales and earnings and plans to highlight its outlook at the Leerink Global Healthcare Conference on March 10, 2026, signaling management’s confidence and increased capital returns to shareholders.
• Next, we will examine how the combination of upbeat 2026 guidance and the new US$100 million buyback influences LeMaitre’s investment narrative.

Find 46 companies with promising cash flow potential yet trading below their fair value.

What Is LeMaitre Vascular's Investment Narrative?

To own LeMaitre Vascular, you need to be comfortable backing a relatively fast‑growing, profitable vascular specialist that now leans harder into shareholder returns. The latest earnings release, with higher 2025 sales and net income, sits alongside 2026 guidance that implies further growth in both revenue and EPS. Layer on top a higher US$0.25 quarterly dividend and a new US$100 million buyback authorization through early 2027, and the short‑term story tilts more toward capital return as a visible catalyst, especially after a strong 3‑month share price run. That said, with the stock already trading close to consensus fair value and at a premium P/E to the broader medical equipment group, the key risk is that expectations have reset higher, leaving less room for disappointment if guidance or execution wobbles.

However, investors should be aware of how full valuation magnifies any setback in execution. LeMaitre Vascular's shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.

Exploring Other Perspectives

LeMaitre’s fair value estimates from three Simply Wall St Community members span from about US$61 to a very large upper bound, underscoring how differently people see the upside. Set that against recent guidance and capital return plans, and it becomes clear that expectations and risk tolerance around this premium‑priced stock can vary sharply, so you may want to compare several viewpoints before deciding how it fits into your portfolio.

Explore 3 other fair value estimates on LeMaitre Vascular - why the stock might be worth 45% less than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your LeMaitre Vascular research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free LeMaitre Vascular research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LeMaitre Vascular's overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.